微流控成像流式细胞仪通过不对称检测时间延伸光学显微镜（ATOM）

Executive Industry Relevance

ATOM addresses the throughput limitation of imaging flow cytometry by enabling high-speed, label-free single-cell imaging at up to 100,000 cells per second while preserving sub-cellular resolution and image contrast. This capability supports high-confidence statistical analysis through multidimensional morphological data, directly enhancing target validation and phenotypic screening in early discovery. By providing label-free biophysical phenotyping, ATOM complements biochemical assays and improves predictive confidence in cellular classification within heterogeneous populations.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Enables interrogation of therapeutic hypotheses through label-free morphological analysis of cellular and subcellular structures.
• Operational Value: Supports functional target validation by de-risking mechanistic ambiguity via high-throughput biophysical phenotyping.
• Predictive Value: Enhances portfolio triage by generating quantitative morphological parameters (e.g., size, circularity) for cytometric classification of cell states and functions.

Screening & Assay Development

• Scientific Value: Prepares validated biological systems for downstream workflows by delivering high-contrast, sub-cellular resolution images without labels or stains.
• Operational Value: Addresses assay standardization and reproducibility through ultrafast line scan rates and consistent optical signal processing.
• Scalability: Highlights screening readiness and platform reuse by enabling imaging flow cytometry at 100,000 cells/s, overcoming traditional throughput bottlenecks.

Translational & Preclinical Research

• Translational Continuity: Supports disease-relevant systems by detecting rare or aberrant cells in heterogeneous populations, as demonstrated with human cell lines and micro-algae.
• Preclinical Alignment: Facilitates continuity from discovery to preclinical validation through label-free imaging that complements biomarker-based assays.
• Risk-Adjusted Decisions: Enables data-driven advancement by linking morphological trends to functional outcomes via scatter plot analysis and manual gating.

Pipeline & Workflow Integration

ATOM integrates into the discovery continuum from hypothesis testing in early discovery to lead identification and preclinical validation, providing label-free imaging that supports mechanistic de-risking and predictive analytics.

• Discovery Biology: Supports hypothesis testing and pathway clarification by enabling complex morphological analysis of cellular structures in microfluidic flow.
• Screening: Delivers assay readiness and reproducibility through high-speed image capture and quantitative parameter extraction from single-cell images.
• Analytics: Provides measurable outputs such as cell size, circularity, and texture for comparative analysis and classification in scatter plots.
• Translational Research: Connects to preclinical continuity by enabling label-free imaging of heterogeneous cell populations, supporting biomarker-independent phenotypic screening.
• Enterprise Reuse: Functions as a reusable platform for high-throughput imaging across model systems, reducing dependency on staining protocols and accelerating assay development cycles.

Operational & Enterprise Impact

• Scientific Value: Predictive confidence through label-free morphological de-risking and reduction of ambiguity in cellular classification.
• Operational Value: Standardization, reproducibility, and scalability via ultrafast imaging and consistent signal-to-noise ratio control (>10 dB).
• Strategic Value: Better go/no-go decisions, capital efficiency, and reduced late-stage biological risk by enabling early detection of rare or aberrant cells.
• Portfolio Impact: Risk-adjusted prioritization and advancement decisions based on quantitative morphological data from high-throughput imaging.

Implementation Considerations

• Requires expertise in optical microscopy, ultrafast laser systems, and microfluidic flow control.
• Needs broadband femtosecond/picosecond near-IR pulsed laser, optical amplifier, diffraction grating, and high-bandwidth oscilloscope.
• Demands cross-team standardization for beam alignment, knife-edge blocking, and fiber length calibration to maintain image contrast and timing.
• Involves adaptation considerations for varying cell types and microfluidic channel dimensions to ensure optimal spectral shower coverage.
• Includes practical limitations such as laser safety requirements and the need for precise optical path alignment to avoid resolution degradation.

Biopharma FAQs